Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 15/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12586302 | 0.91 | EPHX2 (0.51) | KDM4EEPHX2HSD11B1 | |
| SCHEMBL4827794 | 0.90 | HSD11B1 (0.59) | KDM4ETP53TSHREPHX2HSD11B1 | |
| SCHEMBL12586217 | 0.90 | HSD11B1 (0.59) | KDM4ETP53TSHREPHX2HSD11B1 | |
| SCHEMBL12586465 | 0.89 | HSD11B1 (0.47) | KDM4ETP53TSHREPHX2HSD11B1 | |
| SCHEMBL3185119 | 0.88 | HSD11B1 (0.59) | EPHX2HSD11B1 | |
| SCHEMBL12585771 | 0.84 | HSD11B1 (0.46) | EPHX2HSD11B1 | |
| SCHEMBL12586435 | 0.83 | HSD11B1 (0.44) | HSD11B1 | |
| SCHEMBL12585861 | 0.82 | HSD11B1 (0.47) | KDM4EHSD11B1 | |
| SCHEMBL6688873 | 0.81 | HSD11B1 (0.48) | KDM4EEPHX2HSD11B1 | |
| SCHEMBL6092831 | 0.80 | HSD11B1 (0.50) | EPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581476-B1 | AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-16 | — | — | EP | claimed |
| US-20060079506-A1 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICAL N.V. (BE) | 2006-04-13 | — | — | US | claimed |
| WO-2004056744-A1 | ADAMANTYL ACETAMIDES AS HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079506-A1 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | DHCR7, HSD3B2, HSD3B1 | KDM4E 4303/4885TP53 4282/4885TSHR 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.